Investing in innovation: Q&A with Greg Engel
By Mari-Len De Guzman
What does US$175 million and a cannabis R&D Centre of Excellence achieve for a Moncton, N.B.-based licensed cannabis producer? The future. Organigram CEO Greg Engel talks to Grow Opportunity about the details of British American Tobacco’s investment in Organigram, what it means for the company’s future product offerings, employment opportunities, and the company’s global expansion. Engel also share his thoughts on the cannabis industry, the lessons learned over the last two years of legalization and creating a dynamic, more responsive medical cannabis sector.
Guest: Greg Engel, CEO, Organigram